A Phase 4 interventional study of rt-PA and DAPT in Lacunar Stroke, Stroke and Ischemic Stroke, sponsored by Nippon Medical School. Recruiting at 29 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Nippon Medical School · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke). The main questions it aims to answer are:
Is a combination of antiplatelet drugs non-inferior to the current standard tissue plasminogen activator treatment? Does a combination of antiplatelet drugs reduce the bleeding complications than tissue plasminogen activator?
Researchers will compare a combination of antiplatelet drugs to tissue plasminogen activator to see if a combination of antiplatelet drugs works to treat small ischemic stroke (lacunar stroke).
Participants will:
Take a combination of antiplatelet drugs or be given intravenous tissue plasminogen activator Check the neurological status 3 months after stroke, in-person, by phone, or by mail.
21 studies on the registry are indexed under Stroke, Lacunar; 9 are open to participants now.
This study's planned enrollment of 500 is above the median of 60 across 15 interventional studies indexed under Stroke, Lacunar.
Browse Stroke, Lacunar studies →Nippon Medical School is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
located in the corona radiata, putamen, internal capsule, thalamus, or pons; solitary, mainly round or oval, with a maximum diameter ≤ 20 mm; lesions only in the centrum semiovale are not allowed, but extension from the above sites into the centrum semiovale is allowed.
Exclusion Criteria:
Note: This study targets hyper-acute stroke within 4.5 hours. To avoid treatment delay, items marked with * must be judged using the similar examinations that each site normally performs before rt-PA administration.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rt-PA
Drug: DAPT
Recombinant tissue-plasminogen activator treatment. Low-dose (0.6mg/kg) alteplase will be given because this dosage is the only dosage approved in Japan.
Dual antiplatelet therapy with aspirin 200mg and clopidogrel 300mg.
Excellent outcome
Modified Rankin scale score of 0-1
Time frame: 3 months after stroke
Infarct growth between Day 7 and admission
Infarct growth between Day 7 and admission on diffusion-weighted imaging
Time frame: At Day 7
Early neurological deterioration
Increment in NIHSS score by 2 points or more from admission
Time frame: At Day 7
NIHSS score on Day 7
NIHSS score on Day 7
Time frame: At Day 7
Good outcome
mRS 0-2 at 3 months from stroke onset
Time frame: At 3 months
mRS distribution at 3 months
mRS distribution (assessed by shift analysis) at 3 months from onset
Time frame: At 3 months
Ischemic stroke recurrence
Ischemic stroke recurrence during 3 months from onset
Time frame: At 3 months
Cost effectiveness of DAPT
Cost effectiveness analysis comparing DAPT to rt-PA
Time frame: Various (such as at 7 days or 3 months)
Safety - symptomatic intracerebral hemorrhage
symptomatic intracerebral hemorrhage
Time frame: At 24 hours from the initial treatment
Safety - any intracranial bleeding
any intracranial bleeding
Time frame: At 14 days from admission
Safety - other hemorrhagic complications
other hemorrhagic complications
Time frame: At 14 days from admission
Safety - all-cause mortality
all-cause mortality
Time frame: At 3 months
Safety - cerebrovascular death
cerebrovascular death
Time frame: At 3 months
Plan to share: Yes — On reasonable request.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nippon Medical School